
zzso I zzso are new compounds of interest for cancer zzso We performed a study with zzso a new zzso zzso zzso to determine the absolute zzso of the drug given zzso Patients with a zzso confirmed diagnosis of a solid zzso zzso to standard forms of therapy were eligible for the zzso zzso was given orally on day 1 and as a zzso infusion daily on days zzso The treatment course was repeated every 3 zzso In subsequent patient zzso the dose of the oral zzso was escalated from zzso zzso zzso to zzso zzso zzso the dose for zzso administration was fixed at zzso zzso zzso Plasma zzso was performed on day 1 and 2 of the first course and on day 1 of the second course using a validated zzso liquid zzso zzso zzso patients were entered into the study; one patient was not zzso because the treatment course was stopped zzso zzso patients received a total of 47 treatment zzso The absolute zzso of zzso averaged zzso zzso zzso Drug appeared quickly in plasma with a median zzso at zzso zzso zzso or fed state had no significant influence on the zzso of zzso The terminal zzso after administration of oral zzso was zzso zzso zzso zzso similar to the zzso after intravenous zzso The major zzso were zzso and zzso zzso for zzso and zzso occurred on day 8 and day 15 zzso Other zzso predominantly consisted of mild and zzso zzso and zzso and zzso The oral administration of the drug is well zzso zzso administration of zzso I inhibitor zzso results in a low zzso with relatively wide zzso zzso The intravenous route of administration is advised for further development of this promising zzso I zzso 

